Treatment of myocarditis: contemporary approaches and perspective trends

Main Article Content

V. M. Kovalenko
E. G. Nesukay
S. V. Cherniuk
N. S. Polenova
R. M. Kirichenko
A. S. Kozliuk
J. J. Giresh
E.Yu. Titov

Abstract

The choice of adequate tactics for the treatment of myocarditis is particularly relevant today, and the most controversial among modern scientists and practitioners is the question of prescribing etiology-based and pathogenetic treatment. One of the most pressing and complex issues at the present stage is the problem of developing adequate schemes for etiology-based and pathogenetic treatment of severe chronic myocarditis, as so far the only recommended strategy is the treatment of heart failure according to current recommendations. The appointment of etiotropic therapy in patients with myocarditis may be appropriate in the acute phase of the disease and must take into account the results of endomyocardial biopsy. Immunosuppressive therapy should be used only in patients with severe myocarditis in the presence of conclusive evidence of active inflammatory process in the myocardium with mandatory re-examination after completion of its course to monitor safety and efficacy. In the presence of dilatation of the left ventricle and a reduced left ventricle ejection fraction, the basis for the treatment of myocarditis is the patient’s compliance with dietary restrictions and the use of standard heart failure therapy according to current recommendations. However, a large number of issues related to the management of patients with myocarditis remain debatable, so leading world scientists recognize the need for further research to assess the effectiveness of etiology-based and pathogenetic therapy.

Article Details

Keywords:

myocarditis, pathogenetic therapy, immunosuppressants, glucocorticoids

References

Коваленко В.М., Лутай М.І., Сіренко Ю.М., Сичов О.С. Серцево-судинні захворювання: класифікація, стандарти діагностики та лікування.– К.: Моріон, 2020.– 239 с.

Коваленко В.М., Несукай О.Г., Чернюк С.В. та ін. Імуносупресивна терапія у хворих на міокардит: обґрунтування для використання в клінічній практиці // Укр. кардіол. журн.– 2019.– № 4.– С. 7 – 18.

Коваленко В.М., Несукай О.Г., Воронков Л.Г. та ін. Діагностика та лікування міокардиту: рекомендації робочої групи з хвороб міокарда, перикарда, ендокарда та клапанів серця Асоціації кардіологів України (проєкт) // Укр. кардіол. журн.– 2014.– № 3.– С. 15–21.

Рябенко Д.В. Современное состояние проблемы миокардитов // Серцева недостатність та коморбідні стани.– 2018.– № 1.– С. 36–42.

Чернюк С.В. Прогнозування ефективності імуносупресивної терапії у хворих із гострим міокардитом // Експериментальна та клінічна фізіологія і біохімія.– 2019.– № 2 (86).– С. 59–65.

Чернюк С.В., Козлюк А.С. Вивчення ефективності застосування глюкокортикоїдів у хворих з хронічним міокардитом // Вісник Вінницького національного медичного університету.– 2018.– № 4.– С. 686–690.

Ammirati E., Veronese G., Bottiroli M. et al. Update on acute myocarditis // Trends in Cardiovascular Medicine.– 2020. doi: https://doi.org/10.1016/j.tcm.2020.05.008.

Baksi A.J., Kanaganayagam G.S., Prasad S.K. Arrhythmias in viral myocarditis and pericarditis // Card. Electrophysiol. Clin.– 2015.– Vol. 7 (2).– P. 269–281. doi: https://doi.org/10.1016/j.ccep.2015.03.009.

Bracamonte-Baran W., Čiháková D. Cardiac Auto­­­­immunity: Myocarditis // Adv. Exp. Med. Biol.– 2017.– Vol. 1003.– P. 187–221. doi: https://doi.org/10.1007/978-3-319-57613-8_10.

Caforio A.L., Marcolongo R., Jahns R. et al. Immune-mediated and autoimmune myocarditis: clinical presentation, diagnosis and management // Heart Fail. Rev.– 2013.– Vol. 18 (6).– P. 715–732. doi: https://doi.org/10.1007/s10741-012-9364-5.

Caforio A.L., Malipiero G., Marcolongo R., Iliceto S. Myocarditis: a clinical overview // Curr. Cardiol. Rep.– 2017.– Vol. 19 (7).– P. 63. doi: https://doi.org/10.1007/s11886-017-0870-x.

Caforio A.L., Pankuweit S., Arbustini E. et al. Current state of knowledge on aetiology, diagnosis, management and therapy of myocarditis: a position statement of the ESC Working group on myocardial and pericardial diseases // Eur. Heart J.– 2013.– Vol. 34 (33).– P. 2636–2648. doi: https://doi.org/10.1093/eurheartj/eht210.

Chimenti C., Verardo R., Scopelliti F. et al. Myocardial expression of Toll-like receptor 4 predicts the response to immunosuppressive therapy in patients with virus-negative chronic inflammatory cardiomyopathy // Eur. J. Heart Fail.– 2017.– Vol. 19 (7).– P. 915–925. doi: https://doi.org/10.1002/ejhf.796.

Ebert M., Richter S., Dinov B. et al. Evaluation and management of ventricular tachycardia in patients with dilated cardiomyopathy // Heart Rhythm.– 2019.– Vol. 16 (4).– P. 624–631. doi: https://doi.org/10.1016/j.hrthm.2018.10.028.

Escher F., Kühl U., Lassner D. et al. Long-term outcome of patients with virus-negative chronic myocarditis or inflammatory cardiomyopathy after immunosuppressive therapy. // Clin. Res. Cardiol.– 2016.– Vol. 105.– P. 1011–1020. doi: https://doi.org/10.1007/s00392-016-1011-z.

Esher F., Tschoepe C., Lassner D., Schultheiss H.P. Myocarditis and inflammatory cardiomyopathy: from diagnosis to treatment. // Turc. Cardiol. Dem. Ars.– 2015.– Vol. 43 (8).– P. 739–748. doi: https://doi.org/10.5543/tkda.2015.47750.

Frustaci A., Chimenti C. Immunosupressive therapy in myocarditis // Circulation J.– 2014.– Vol. 79.– P. 4–7.

doi: https://doi.org/10.1253/circj.CJ-14-1192.

Frustaci A., Russo M.A., Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. // Eur. Heart J.– 2009.– Vol. 30.– P. 1995–2002. doi: https://doi.org/10.1093/eurheartj/ehp249.

Fung G., Luo H., Qiu Y. et al. Myocarditis // Circ. Res.– 2016.– Vol. 118 (3).– P. 496–514. doi: https://doi.org/10.1161/CIRCRESAHA.115.306573.

Ginsberg F., Parrillo J.E. Fulminant myocarditis // Crit. Care Clin.– 2013.– Vol. 29 (3).– P. 465–483. doi: https://doi.org/10.1016/j.ccc.2013.03.004.

Guglin M., Nallamshetty L. Myocarditis: diagnosis and treatment // Curr. Treat Options Cardiovasc. Med.– 2012.– Vol. 14 (6).– P. 637–651. doi: https://doi.org/10.1007/s11936-012-0204-7.

Hase H., Saito T., Yamazaki H. et al. Successful treatment using corticosteroids in early phase of eosinophilic myocarditis with eosinophilic granulomatosis with polyangiitis // J. Cardiology Cases.– 2016.– Vol. 14 (6).– P. 177–180. doi: https://doi.org/10.1016/j.jccase.2016.08.006.

Herda L.R., Felix S.B., Staudt A. Immunoadsorption in patients with dilated cardiomyopathy. // Atherosclerosis Supplements.– 2009.– Vol. 10 (5).– Р. 126–128. doi: https://doi.org/10.1016/S1567-5688(09)71826-4.

Heymans S., Eriksson U., Lehtonen J., Cooper T.L. The quest for new approaches in myocarditis and inflammatory cardiomyopathy // J. Am. Coll. Cardiol.– 2016.– Vol. 68 (21).– P. 2348–2364. doi: https://doi.org/10.1016/j.jacc.2016.09.937.

Ikeda U., Kasai H., Izawa A. et al. Immunoadsorption Therapy for Patients with Dilated Cardiomyopathy and Heart Failure // Curr. Cardiol. Rev.– 2008.– Vol. 4 (3).– P. 219–222. doi: https://doi.org/10.2174/157340308785160534.

Kindermann I., Barth C., Mahfoud F. et al. Update on myocarditis // J. Am. Coll. Cardiol. 2012.– Vol. 59 (9).– P. 779–792. doi: https://doi.org/10.1016/j.jacc.2011.09.074.

Krejci J., Mlejnek D., Sochorova D., Nemec P. Inflammatory cardiomyopathy: a current view on pathophysiology, diagnosis and treatment // BioMed Research International.– 2016.– P. 1–11. doi: https://doi.org/10.1155/2016/4087632.

Lu C., Qin F., Yan Y. et al. Immunosupressive treatment for myocarditis: a meta-analysis of randomized controlled trials // J. Cardiovasc. Med.– 2017.– Vol. 17.– P. 631–637. doi: https://doi.org/10.2459/jcm.0000000000000134.

Lu M., Samblanet K., Roberts C. Myocarditis: A Heart on Fire // Curr. Sports Med. Rep.– 2020.– Vol. 19 (3).– P. 110–112. doi: https://doi.org/10.1249/JSR.0000000000000698.

Luyt C.E., Hékimian G., Ginsberg F. What’s new in myocarditis? // Intensive Care Med.– 2016.– Vol. 42 (6).– P. 1055–1057. doi: https://doi.org/10.1007/s00134-015-4017-5.

Maisch B., Alter P. Treatment options in myocarditis and inflammatory cardiomyopathy: focus on i. v. immunoglobulins // Herz.– 2018.– Vol. 43 (5).– P. 423–430. doi: https://doi.org/10.1007/s00059-018-4719-x.

Maisch B., Ristic A.D., Pankuweit S. Inflammatory cardiomyopathy and myocarditis // Herz.– 2017.– Vol. 42 (4).– P. 425–438. doi: https://doi.org/10.1007/s00059-017-4569-y.

Maisch B. Cardio-Immunology of Myocarditis: Focus on Immune Mechanisms and Treatment Options // Frontiers in Cardiovascular Medicine.– 2019.– Vol. 6.– P. 48. doi: https://doi.org/10.3389/fcvm.2019.00048.

Merken J., Hazebroek M., Van Paassen P. et al. Immunosuppressive Therapy Improves Both Short- and Long-Term Prognosis in Patients With Virus Negative Nonfulminant Inflammatory Cardiomyopathy // Circulation: Heart Failure.– 2018.– Vol. 11.– Р. e004228. doi: https://doi.org/10.1161/ CIRCHEARTFAILURE.117.004228.

Pinto Y.M., Elliott P.M., Arbustini E. et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases // Eur. Heart J.– 2016.– Vol. 37 (23).– P. 1850–1858. doi: https://doi.org/10.1093/eurheartj/ehv727.

Ponikowski P., Voors A.A., Anker S.D. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure // Eur. Heart J.– 2016.– Vol. 37.– P. 2129–2200. doi: https://doi.org/10.1093/eurheartj/ehw128.

Qin F., Yan Y., Liu T., Li J., Chen H. Immunosuppressive treatment for myocarditis: a meta-analysis of randomized

controlled trials // J. Cardiovasc. Med. Hagerstown.– 2016.– Vol. 17 (8).– P. 631–637. doi: https://doi.org/10.2459/JCM.0000000000000134.

Robinson J., Hartling L., Vandermeer B., Klassen T.P. Intravenous immunoglobulin for presumed viral myocarditis in children and adults // Cochrane Database Syst. Rev.– 2015.– Vol. 20 (5).– P. CD004370. doi: 10.1002/14651858.CD00437.

Schultheiss H.P., Fairweather D., Caforio A.L.P. et al. Dilated cardiomyopathy // Nat Rev Dis Primers.– 2019.– Vol. 5(1).– P. 32. doi: https://doi.org/10.1038/s41572-019-0084-1.

Schultheiss H.P., Escher F. Chapter Tratment of myocarditis in ESC CardioMed (3 edn.) / Еds. A.J. Camm, T.F. Luscher, G. Maurer, P.W. Serruys. – Oxford University Press.– 2018. doi: https://doi.org/10.1093/med/9780198784906.003.0368.

Schultheiss H.P., Piper C., Sowade O. et al. Betaferon in chronic viral cardiomyopathy (BICC) trial: effects of

interferon-b treatment in patients with chronic viral cardiomyopathy // Clin. Res. Cardiol.– 2016.– Vol. 105.– P. 763–769. doi: https://doi.org/10.1007/s00392-016-0986-9.

Seferovic P.M., Polovina M., Bauersachs J. et al. Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology // Eur. J. Heart Failure.– 2019.– Vol. 21.– P. 553–576. doi: 10.1002/ejhf.1461.

Shah Z., Mohammed M., Vuddanda V. et al. National Trends, Gender, Management, and Outcomes of Patients Hospitalized for Myocarditis // Am. J. Cardiol.– 2019.– Vol. 124 (1).– P. 131–136. doi: https://doi.org/10.1016/j.amjcard.2019.03.036.

Sinagra G.F., Anzini M., Pereira N.L. et al. Myocarditis in clinical practice // Mayo Clin. Proc.– 2016.– Vol. 91 (9).– P. 1256–1266. doi: 10.1016/j.mayocp.2016.05.013.

Staudt A., Felix S.B. Immunoadsorption in dilated cardiomyopathy // Transfusion and Apheresis Science.– 2007.–

Vol. 37 (2).– P. 187–190. https://doi.org/10.1016/j.transci.2007.08.008.

Tschöpe C., Cooper L.T., Torre-Amione G., Van Linthout S. Management of Myocarditis-Related Cardiomyopathy in Adults // Circ. Res.– 2019.– Vol. 124 (11).– P. 1568–1583. doi: https://doi.org/10.1161/CIRCRESAHA.118.313578.

Van Linthout S., Tschöpe C. Viral myocarditis: a prime example for endomyocardial biopsy-guided diagnosis and therapy // Curr. Opin. Cardiol.– 2018.– Vol. 33 (3).– P. 325–333. doi: https://doi.org/10.1097/HCO.0000000000000515.

Van Tassell B.W., Raleigh J.M., Abbate A. Targeting interleukin-1 in heart failure and inflammatory heart disease // Curr. Heart Fail. Rep.– 2015.– Vol. 12 (1).– P. 33–41. doi: https://doi.org/10.1007/s11897-014-0231-7.

Yen C.Y., Hung M.C., Wong Y.C. et al. Role of intravenous immunoglobulin therapy in the survival rate of pediatric patients with acute myocarditis: A systematic review and meta-analysis // Sci. Rep.– 2019.– Vol. 9 (1).– P. 1045–1049. doi: https://doi.org/10.1038/s41598-019-46888-0.

Yusuf S.W., Durand J.B., Banchs J. Endocarditis and Myocarditis: A Brief Review // Expert Rev. Cardiovasc. Ther.– 2012.– Vol. 10 (9).– P. 1153–1164. doi: https://doi.org/10.1586/erc.12.107.

Most read articles by the same author(s)

<< < 1 2